RESULTS	23 of 96 ( 240 % [ 158-337 ] ) women given pertuzumab plus docetaxel ( group D ) had a pathological complete response , as did 18 of 107 ( 168 % [ 103-253 ] ) given pertuzumab and trastuzumab ( group C ) .\